These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 35379762)

  • 41. Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort.
    Tsagkas C; Naegelin Y; Amann M; Papadopoulou A; Barro C; Chakravarty MM; Gaetano L; Wuerfel J; Kappos L; Kuhle J; Granziera C; Sprenger T; Magon S; Parmar K
    Eur J Neurol; 2021 Dec; 28(12):4153-4166. PubMed ID: 34487400
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysis.
    Calvi A; Mendelsohn Z; Hamed W; Chard D; Tur C; Stutters J; MacManus D; Kanber B; Wheeler-Kingshott CAMG; Barkhof F; Prados F
    Eur J Neurol; 2024 Jan; 31(1):e16092. PubMed ID: 37823722
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Brain atrophy and physical disability in primary progressive multiple sclerosis: A volumetric study.
    Galego O; Gouveia A; Batista S; Moura C; Machado E
    Neuroradiol J; 2015 Jun; 28(3):354-8. PubMed ID: 26246109
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials.
    Nicholas RS; Han E; Raffel J; Chataway J; Friede T
    Mult Scler; 2019 Oct; 25(11):1462-1471. PubMed ID: 30141723
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high-dose pharmaceutical-grade biotin (MD1003).
    Collongues N; Kuhle J; Tsagkas C; Lamy J; Meyer N; Barro C; Parmar K; Amann M; Wuerfel J; Kappos L; Moreau T; de Seze J
    Brain Behav; 2021 Feb; 11(2):e01998. PubMed ID: 33314801
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of Serum Neurofilament Light Levels With Long-term Brain Atrophy in Patients With a First Multiple Sclerosis Episode.
    Plavina T; Singh CM; Sangurdekar D; de Moor C; Engle B; Gafson A; Goyal J; Fisher E; Szak S; Kinkel RP; Sandrock AW; Su R; Kieseier BC; Rudick RA
    JAMA Netw Open; 2020 Nov; 3(11):e2016278. PubMed ID: 33151313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study.
    Blinkenberg M; Kjellberg J; Ibsen R; Magyari M
    Mult Scler Relat Disord; 2020 Nov; 46():102567. PubMed ID: 33296969
    [TBL] [Abstract][Full Text] [Related]  

  • 48. N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis.
    Trentini A; Comabella M; Tintoré M; Koel-Simmelink MJ; Killestein J; Roos B; Rovira A; Korth C; Ottis P; Blankenstein MA; Montalban X; Bellini T; Teunissen CE
    J Neurol; 2014 Dec; 261(12):2338-43. PubMed ID: 25228004
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multiple sclerosis by phenotype in Germany.
    Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
    Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.
    Tutuncu M; Tang J; Zeid NA; Kale N; Crusan DJ; Atkinson EJ; Siva A; Pittock SJ; Pirko I; Keegan BM; Lucchinetti CF; Noseworthy JH; Rodriguez M; Weinshenker BG; Kantarci OH
    Mult Scler; 2013 Feb; 19(2):188-98. PubMed ID: 22736750
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis.
    Fedičová M; Mikula P; Gdovinová Z; Vitková M; Žilka N; Hanes J; Frigová L; Szilasiová J
    Medicina (Kaunas); 2023 Apr; 59(5):. PubMed ID: 37241097
    [No Abstract]   [Full Text] [Related]  

  • 52. Diagnostic and prognostic performance of plasma neurofilament light chain in multiple system atrophy: a cross-sectional and longitudinal study.
    Peng L; Wan L; Liu M; Long Z; Chen D; Yuan X; Tang Z; Fu Y; Zhu S; Lei L; Wang C; Peng H; Shi Y; He L; Yuan H; Wan N; Hou X; Xia K; Li J; Chen C; Qiu R; Tang B; Chen Z; Jiang H
    J Neurol; 2023 Sep; 270(9):4248-4261. PubMed ID: 37184660
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Involvement of cytotoxic Eomes-expressing CD4
    Raveney BJE; Sato W; Takewaki D; Zhang C; Kanazawa T; Lin Y; Okamoto T; Araki M; Kimura Y; Sato N; Sano T; Saito Y; Oki S; Yamamura T
    Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836594
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials.
    Kappos L; Weinshenker B; Pozzilli C; Thompson AJ; Dahlke F; Beckmann K; Polman C; McFarland H; ;
    Neurology; 2004 Nov; 63(10):1779-87. PubMed ID: 15557490
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interferon Beta for primary progressive multiple sclerosis.
    Rojas JI; Romano M; Ciapponi A; Patrucco L; Cristiano E
    Cochrane Database Syst Rev; 2010 Jan; (1):CD006643. PubMed ID: 20091602
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interferon beta for primary progressive multiple sclerosis.
    Rojas JI; Romano M; Ciapponi A; Patrucco L; Cristiano E
    Cochrane Database Syst Rev; 2009 Jan; (1):CD006643. PubMed ID: 19160292
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial.
    Wolinsky JS; Montalban X; Hauser SL; Giovannoni G; Vermersch P; Bernasconi C; Deol-Bhullar G; Garren H; Chin P; Belachew S; Kappos L
    Ann Neurol; 2018 Oct; 84(4):527-536. PubMed ID: 30155979
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biomarkers of disability worsening in inactive primary progressive multiple sclerosis.
    Baeva ME; Tottenham I; Koch M; Camara-Lemarroy C
    J Neuroimmunol; 2024 Feb; 387():578268. PubMed ID: 38157653
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.
    Barro C; Benkert P; Disanto G; Tsagkas C; Amann M; Naegelin Y; Leppert D; Gobbi C; Granziera C; Yaldizli Ö; Michalak Z; Wuerfel J; Kappos L; Parmar K; Kuhle J
    Brain; 2018 Aug; 141(8):2382-2391. PubMed ID: 29860296
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study.
    Uphaus T; Steffen F; Muthuraman M; Ripfel N; Fleischer V; Groppa S; Ruck T; Meuth SG; Pul R; Kleinschnitz C; Ellwardt E; Loos J; Engel S; Zipp F; Bittner S
    EBioMedicine; 2021 Oct; 72():103590. PubMed ID: 34571362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.